Which EGFR mutations in lung adenocarcinoma are targetable and what are the recommended treatments?

Targetable EGFR Mutations in Lung Adenocarcinoma

The targetable EGFR mutations in lung adenocarcinoma include common sensitizing mutations (exon 19 deletions and L858R), uncommon sensitizing mutations (G719X, L861Q, S768I), exon 20 insertions, and the acquired resistance mutation T790M, each requiring specific treatment approaches based on mutation type and line of therapy. 1

Common Sensitizing Mutations (Exon 19 Deletions and L858R)

First-Line Treatment

• Osimertinib is the standard of care for treatment-naive patients with exon 19 deletions or L858R mutations 2
• These mutations represent the most frequent EGFR alterations and demonstrate excellent response to third-generation TKIs 1
• Exon 19 deletions show superior outcomes compared to L858R, with higher overall response rates (55.2% vs 43.7%) and longer progression-free survival (14.4 vs 11.4 months) 3

After Osimertinib Failure

• Platinum-based chemotherapy remains standard of care when no new targetable mutations emerge 1
• Amivantamab plus carboplatin and pemetrexed is recommended for progressive disease on osimertinib 2
• Repeat molecular testing (tissue or ctDNA) is essential to identify acquired resistance mechanisms 1

Uncommon Sensitizing Mutations

Major Uncommon Mutations (G719X, L861Q, S768I)

• Afatinib and osimertinib should be considered as monotherapy for these mutations 1
• Afatinib is the only FDA-approved EGFR TKI specifically for G719X, S768I, and L861Q mutations, demonstrating similar efficacy to common mutations when used at 40 mg/day 1
• Osimertinib shows activity in these major uncommon alterations and serves as an alternative treatment option 1
• Chemotherapy should be considered when evidence favoring TKI is limited or missing 1

Important Caveat

• Single uncommon mutations may respond poorly to first-generation TKIs, with first-line chemotherapy showing better overall survival (HR: 0.31) compared to first/second-generation TKIs 4
• However, patients with compound/double uncommon mutations demonstrate significantly better outcomes with TKIs (HR: 0.07) and should receive targeted therapy 4

EGFR Exon 20 Insertions

Treatment Approach

• Platinum-based chemotherapy is recommended as first-line therapy, preferably without checkpoint inhibitors due to potential toxicity with subsequent targeted therapy 1
• These insertions are resistant to standard EGFR TKIs due to disruption of the α-C helix structure 1

Second-Line Options

• Amivantamab or mobocertinib should be considered after platinum failure 1
• Both agents are FDA-approved for EGFR exon 20 insertion mutations after first-line chemotherapy 1
• Amivantamab is a bispecific monoclonal antibody targeting both EGFR and MET 1
• Mobocertinib is a selective oral TKI targeting EGFR and HER2 exon 20 insertions 1

Acquired T790M Resistance Mutation

• Osimertinib is the standard treatment for patients developing T790M after first- or second-generation EGFR TKIs 2
• T790M occurs as an acquired resistance mechanism and confers sensitivity to third-generation TKIs 1
• Germline T790M mutations (rare, ~1% of NSCLCs) also respond to osimertinib with median PFS of 20.4 months 5

On-Target Resistance After Osimertinib

Resistance Mutations

• C797S (most common), L718Q, L792F, and G796S develop in ~15% of patients after first-line osimertinib 1
• These mutations do not confer resistance to earlier generation TKIs, allowing potential benefit from switching to first-generation inhibitors 1

Treatment Strategy

• Platinum chemotherapy is standard of care in clinical practice 1
• Alternative on-target therapies (TKIs, monoclonal antibodies, antibody-drug conjugates) should be considered preferentially in clinical trial settings 1
• Amivantamab shows clinical efficacy alone or combined with lazertinib 1

Off-Target Resistance Mechanisms

MET Amplification

• Occurs in 10-15% of patients as the most frequent off-target resistance mechanism to osimertinib 1
• Combination strategies with MET inhibitors plus osimertinib show promising results in clinical trials 1
• Osimertinib plus savolitinib achieved 30% response rate in MET-amplified tumors 1

HER2 Amplification

• Represents another targetable off-target resistance mechanism 1
• Patients should be prioritized for molecularly-driven clinical trials targeting specific resistance mechanisms 1

Concurrent Targetable Alterations

• When multiple targetable alterations coexist, comprehensive NGS analysis should identify the dominant clone 1
• Platinum-based chemotherapy with or without TKIs should be prioritized when co-alterations are confirmed 1
• EGFR TKIs show generally good response rates but inferior outcomes compared to single alterations 1
• Rebiopsy at resistance is essential to detect acquired mechanisms and guide combination strategies 1

Critical Pitfalls to Avoid

Immunotherapy Considerations

• Avoid checkpoint inhibitors in EGFR-mutant NSCLC due to limited benefit and risk of hyperprogressive disease (20% incidence) 1
• Responses vary by mutation type (uncommon > L858R > exon 19 deletions) 1
• Combinations of TKIs plus PD-1/PD-L1 inhibitors carry increased toxicity risk, particularly pneumonitis (38% with durvalumab plus osimertinib) 1
• Long half-life of checkpoint inhibitors may cause toxicity when TKIs are given subsequently 1

Testing Requirements

• Always obtain EGFR testing results before initiating immunotherapy-based treatment in newly diagnosed advanced NSCLC 1
• Repeat molecular profiling at progression is mandatory to guide subsequent therapy 1